Key facts
- It has raised $5.0M; the latest was Seed Round ($5.0M) in Apr 2026.
- Notable investors include Berkley Center for Entrepreneurship.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ScriptBio AI
- ·The full record, as it builds
Funding rounds
No funding rounds for ScriptBio AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ScriptBio AI
Developer of artificial intelligence tools designed to accelerate drug discovery and molecular research. The company's platform integrates generative models, automates molecular design, enables predictive simulations, supports validation workflows, and provides scalable infrastructure, enabling pharmaceutical companies, biotechnology firms, and academic institutions to accelerate discovery, reduce development timelines, improve accuracy in molecular predictions, and expand innovation opportunities in therapeutic development.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- scriptbio.ai/
- Ownership
- Privately Held (backing)
ScriptBio AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ScriptBio AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ScriptBio AI in its N-PORT filings yet. We sweep new filings monthly.